Evidence map›Paper›PMID 41781620›Full record

ArticleNature2026

A glucocorticoid-FAS axis controls immune evasion during metastatic seeding.

Monica Cassandras, Xavier Sanchez, Lauren Hsu, Yu Huang, Adam J Getzler, Debolina Ganguly, Pilar Baldominos, Ia Codinachs, Jeffrey Chuong, Elizabeth E Martin and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Monica CassandrasDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2379-503X
Xavier SanchezDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0897-0661
Lauren HsuDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6035-7381
Yu HuangDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Adam J GetzlerDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8091-3851
Debolina GangulyDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pilar BaldominosDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4988-6290
Ia CodinachsDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jeffrey ChuongDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0009-9382-2145
Elizabeth E MartinBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Blake E SmithDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9878-8198
Eleonora MarinaDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0009-1892-1733
Milos SpasicDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Xingping QinJohn B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3263-0843
Heather A ParsonsDepartment of Medicine, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8178-6612
Erica L MayerDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Kristopher A SarosiekJohn B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4618-5085
Stephanie K DouganDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2263-363X
Elizabeth A MittendorfParker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute, Boston, MA, USA.
Sandra S McAllisterBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5111-5903
Ya-Chieh HsuHarvard Stem Cell Institute, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0178-7373
Judith AgudoDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. judith_agudo@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-3576-3169

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Metastasis is the major cause of death for patients with triple-negative breast cancer and other solid malignancies. Metastases arise from cancer cells that disseminate from the original tumour, survive systemic immune surveillance and colonize new organs

Indexed as

fas ReceptorGlucocorticoidsImmune EvasionNeoplasm MetastasisReceptors, GlucocorticoidTriple Negative Breast NeoplasmsTumor EscapeAnimalsCD8-Positive T-LymphocytesCell Line, TumorFas Ligand ProteinFemaleHumansImmunotherapyKiller Cells, NaturalMiceFas Ligand Proteinfas ReceptorGlucocorticoidsReceptors, Glucocorticoid

Identifiers

PMID41781620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.